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Abstract
Status asthmaticus continues to be significant cause of intensive
care admission, morbidity, and mortality in pediatric populations.
Furthermore, despite improved outpatient management and
broader use of controller medications, patients with severe status
asthmaticus account for a notable proportion of these admissions.
There is variability in management and outcomes between
institutions; however, early and aggressive management to avoid
respiratory failure is paramount. In those patients who progress to
develop severe respiratory failure, extracorporeal life support
(ECLS) can be a life-saving therapy. Here, we briefly overview the
use of ECLS for status asthmaticus, as reported through the
Extracorporeal Life Support Organization, including the specific
institutional experience at Children’s Healthcare of Atlanta at
Egleston, and consider how earlier initiation of ECLS may benefit
patients with severe status asthmaticus refractory to conventional
medical therapy.
The Extracorporeal Life Support Organization (ELSO) registry
reports 64 uses of ECLS during the period from 1986 to
2007, including 13 patients from Children’s Healthcare of
Atlanta at Egleston, as presented by Hebbar and coworkers
[1] in their discussion of extracorporeal life support (ECLS)
for refractory severe status asthmaticus (SSA). Overall
survival was 100% in the Egleston cohort and 92% in the
remaining 51 patients reported in the ELSO registry. It is of
interest to note that all of the 13 survivors from the Egleston
series had no reported neurological sequelae. This outcome
is comparable to the 6% incidence of neurological
complications (seizure and intracranial hemorrhage) observed
in the larger group; however, in neither group were
neurological sequelae correlated with overall outcome.
The observed characteristics of patients receiving ECLS for
SSA was similar between the two groups. In general, patients
who received ECLS had a median age of 10 years; before
ECLS they had a serum pH of less than 7.0, an arterial
carbon dioxide tension (PaCO2) above 120 torr, and an
arterial oxygen tension above 50 torr. The percentage of
patients in whom venovenous (VV) cannulation was used was
higher in the Egleston group than in the ELSO group (92%
versus 82%), but over time more patients underwent VV
cannulation. Despite these demographic characteristics,
there were no statistically significant differences in survival
and outcome between the two groups.
Although previous studies [2,3] have considered outcomes
for ECLS for status asthmaticus in adults, the work of Hebbar
and coworkers [1] is the first to discuss pediatric outcomes
comprehensively. In our opinion, the clinical outcomes
observed in both the Egleston and the larger ELSO series
support the early use of ECLS in status asthmaticus, and
moreover they highlight the need to define clinical parameters
that should prompt strong consideration of ECLS. We
advocate a system that first identifies patients at high risk for
developing refractory status asthmaticus: those with history
of multiple intubations and/or respiratory failure requiring
intubation within 6 hours of admission; those with
hemodynamic instability and/or neurological impairment at
time of admission; and those with a duration of respiratory
failure greater than 12 hours despite maximal medical
therapy, as defined by institutional availability. We are
reluctant to propose distinct serum pH and PaCO2 values as
pre-ECLS criteria, given there is no correlation of these
factors with survival. However, in general, sustained PaCO2
retention above 100 mmHg and persistent serum pH below
7.0 should warrant discussion of ECLS.
Where available, ECLS referral should be made early and
decisively. There are clear risks associated with ECLS, but
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avoidance of cardiopulmonary arrest, attenuation of lung
injury associated with prolonged mechanical ventilation at
high pressures, and reduction in the systemic toxicities
associated with medical therapies for SSA should be among
the goals of therapy with ECLS for refractory status asth-
maticus. Cannulation strategies should be patient specific.
However, the recent trend toward VV cannulation for SSA
reported in the ELSO registry is noted and reasonable,
because this mode allows for preservation of arterial vascular
integrity and provides sufficient pulmonary support during the
acute period of illness in those patients without cardio-
vascular compromise. The recent availability of percutaneous
insertion kits and new, double-lumen single cannulas that range
in size from 13 to 32 Fr make implementation of VV support in
children and adults potentially even easier and safer. If ECLS
were considered at the time of presentation based on the
aforementioned criteria, it is possible that patients could require
shorter ECLS courses, because they would not yet have
developed the severe respiratory, hemodynamic, and metabolic
derangements that may prolong the duration of ECLS. The
experience from Children’s Healthcare of Atlanta at Egleston
successfully demonstrates the use of ECLS as an adjunctive
strategy for managing SSA. The work there is both important
and relevant, because it illustrates consistent, positive
outcomes over time with use of this therapy.
SSA is a self-limited, reversible disease process, which - if
treated aggressively at the onset - does not have to be fatal. It
is of interest that although use of ECMO in adults is still a
rarity, a recent review of adult ECMO also focused on use in
status asthmaticus [4]. Both the adult and pediatric studies
have found small numbers of patients, but it is unknown
whether this reflects the small numbers of patients who
develop refractory status asthmaticus or just the fact that
ECMO is rarely considered, no matter how bad the
respiratory failure associated with asthma becomes. The
authors might suggest that the latter is likely. With current
technology, ECMO is safer and easier to perform than it has
ever been. Perhaps raising the visibility of this technique as a
support tool in severe asthma would decrease the mortality
rate and improve patient care in children and adults alike.
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